- Home
- NFJ vs AGIO Comparison
NFJ vs AGIO Comparison
Compare NFJ & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFJ
- AGIO
- Stock Information
- Founded
- NFJ 2005
- AGIO 2007
- Country
- NFJ United States
- AGIO United States
- Employees
- NFJ N/A
- AGIO N/A
- Industry
- NFJ Finance: Consumer Services
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- NFJ Finance
- AGIO Health Care
- Exchange
- NFJ Nasdaq
- AGIO Nasdaq
- Market Cap
- NFJ 1.1B
- AGIO 1.4B
- IPO Year
- NFJ N/A
- AGIO 2013
- Fundamental
- Price
- NFJ $11.89
- AGIO $27.32
- Analyst Decision
- NFJ
- AGIO Buy
- Analyst Count
- NFJ 0
- AGIO 8
- Target Price
- NFJ N/A
- AGIO $56.00
- AVG Volume (30 Days)
- NFJ 223.5K
- AGIO 524.5K
- Earning Date
- NFJ 01-01-0001
- AGIO 05-01-2025
- Dividend Yield
- NFJ 9.01%
- AGIO N/A
- EPS Growth
- NFJ N/A
- AGIO N/A
- EPS
- NFJ N/A
- AGIO 11.45
- Revenue
- NFJ N/A
- AGIO $37,035,000.00
- Revenue This Year
- NFJ N/A
- AGIO $40.62
- Revenue Next Year
- NFJ N/A
- AGIO $216.26
- P/E Ratio
- NFJ N/A
- AGIO $2.39
- Revenue Growth
- NFJ N/A
- AGIO 25.96
- 52 Week Low
- NFJ $10.45
- AGIO $23.42
- 52 Week High
- NFJ $12.86
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- NFJ 58.32
- AGIO 41.34
- Support Level
- NFJ $11.65
- AGIO $27.78
- Resistance Level
- NFJ $11.90
- AGIO $31.55
- Average True Range (ATR)
- NFJ 0.16
- AGIO 1.38
- MACD
- NFJ 0.08
- AGIO -0.03
- Stochastic Oscillator
- NFJ 98.84
- AGIO 2.98
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.